Genetic modulation of tumor antigen presentation

Trends in Biotechnology

Volumn 18, Issue 4, 2000, Pages 167-172

  Xu, Minzhen ^a   Qiu, Gang ^a   Jiang, Zhong ^b   Von Hofe, Eric ^a   Humphreys, Robert E ^a  

^a Antigen Express Inc   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN; TUMOR ANTIGEN; TUMOR VACCINE;

ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; GENE TRANSFER; GENETIC TRANSFECTION; IMMUNOTHERAPY; PRIORITY JOURNAL; PROTEIN INDUCTION; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; ENDOPLASMIC RETICULUM; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOTHERAPY; NEOPLASM METASTASIS; VACCINES, SYNTHETIC;

EID: 0034176773     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-7799(00)01421-9     Document Type: Review

References (52)

1. Greten, T.F. andjaffee, E.M. (1999) Cancer vaccine. J. Clin. Oncol. 17, 1047-1060
2. Nawrocki, S. and Mackiewicz, A. (1999) Genetically modified tumour vaccines - where we are today. Cancer Treat. Rev. 25, 29-46
3. Rosenberg, S.A. (1997) Cancer vaccine based on the identification of genes encoding cancer regression antigens. Immunol. Today 18, 175-181
4. Lord, E.M. and Frelinger, J.G. (1998) Tumor immunotherapy: cytokines and antigen presentation. Cancer Immunol. Immunother. 46, 75-81
5. Hellstrom, K.E. et al. (1995) Can co-stimulated tumor immunity be therapeutically efficacious? Immunol. Rev. 145, 123-145
6. + T cell responses in antitumor immunity. Curr. Opin. Immunol. 10, 588-594
7. +) T cells in the antitumor immune response. J. Exp. Med. 188, 2357-2368
8. Armstrong, T.D. et al. (1998) Tumor antigen presentation: changing the rules. Cancer Immunol. Immunother. 46, 70-74
9. + T cells in vitro and are APCs for tumor-encoded antigens in vivo. J. Immunother. 21, 218-224
10. + T lymphocytes. J. Immunol 160, 661-666
11. +) T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 96, 2982-2987
12. Baskar, S. et al. (1994) MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice. Cell. Immunol. 155, 123-133
13. Armstrong, T.D. et al. (1997) Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc. Natl. Acad. Sci. U. S. A. 94, 6886-6891
14. Martin, B.K. et al. (1999) Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth. J. Immunol. 162, 6663-6670
15. Chen, P.W. and Ananthaswamy, H.N. (1993) Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2. J. Immunol. 151, 244-255
16. James, R.F. et al. (1991) The effect of class II gene transfection on the tumourigenicity of the H-2K-negative mouse leukaemia cell line K36.16. Immunology 72, 213-218
17. + tumor cells. J. Immunol. 149, 2391-2396
18. Qiu, G. et al. (1999) Cancer immunotherapy by antisense suppression of li protein in MHC class II-positive tumor cells. Cancer Immunol. Immunother. 48, 499-506
19. de Visser, K.E. and Kast, W.M. (1999) Effects of TGF-beta on the immune system: implications for cancer immunotherapy. Leukemia 13, 1188-1199
20. Costello, R.T. et al. (1999) Tumor escape from immune surveillance. Arch. Immunol. Ther. Exp. (Warsz) 47, 83-88
21. Restifo, N.P. et al. (1993) Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I. J. Immunother. 14, 182-190
22. Seliger, B. et al. (1997) TAP off - tumors on. Immunol. Today 18, 292-299
23. Brooks, A.G. et al. (1994) Antigen presentation and assembly by mouse I-Ak class II molecules in human APC containing deleted or mutated HLA DM genes. J. Immunol. 153, 5382-5392
24. Bosshart, H. andjarrett, R.F. (1998) Deficient major histocompatibility complex class II antigen presentation in a subset of Hodgkin's disease tumor cells. Blood 92, 2252-2259
25. Yazawa, T. et al. (1999) Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer. J. Pathol. 187, 191-199
26. Jiang, Z. et al. (1999) Invariant chain expression in colon neoplasms. Virchows Archiv 435, 32-36
27. Koretz, K. et al. (1989) Correlation of HLA-D/Ii antigen expression in breast carcinoma with local lymphohistiocytic infiltration reveals considerable dysregulation in a subset of tumors. Int. J. Cancer 44, 816-822
28. Jabrane-Ferrat, N. et al. (1990) Effect of gamma interferon on HLA class-I and -II transcription and protein expression in human breast adenocarcinoma cell lines. Int. J. Cancer 45, 1169-1176
29. Moller, P. et al. (1989) Expression of HLA-A, -B, -C, -DR, -DP, -DQ, and of HLA-D-associated invariant chain (Ii) in non-neoplastic mammary epithelium, fibroadenoma, adenoma, and carcinoma of the breast. Am. J. Pathol. 135, 73-83
30. Ioachim, H.L. et al. (1996) Lymphoid monoclonal antibodies reactive with lung tumors. Diagnostic applications. Am. J. Surg. Pathol. 20, 64-71
31. Moller, P. et al. (1991) Frequency of abnormal expression of HLA-A,B,C and HLA-DR molecules, invariant chain, and LFA-3 (CD58) in colorectal carcinoma and its impact on tumor recurrence. Int. J. Cancer (Suppl.) 6, 155-162
32. Moller, P. et al. (1991) Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma. Cancer Res. 51, 729-736
33. O'Keane, J.C. et al. (1992) Analysis of epithelial and lymphoid phenotypic markers in relation to growth pattern of colorectal adenomas. Hum. Pathol. 23, 1038-1043
34. Mechtersheimer, G. et al (1990) Expression of HLA-A,B,C, beta 2-microglobulin (beta 2m), HLA-DR, -DP, -DQ and of HLA-D-associated invariant chain (Ii) in soft-tissue tumors. Int. J. Cancer 46, 813-823
35. Saito, T. et al. (1996) MHC class II antigen-associated invariant chain on renal cell cancer may contribute to the anti-tumor immune response of the host. Cancer Lett. 109:15-21
36. Spiro, R.C. et al. (1984) Identification of hairy cell leukemia subset defining p35 as the human homologue of Ii. Leuk. Res. 8, 55-62
37. + T cells. Crit. Rev. Immunol. 16, 359-379
38. Newcomb, J.R. and Cresswell, P. (1993) Characterization of endogenous peptides bound to purified HLA-DR molecules and their absence from invariant chain-associated alpha beta dimers. J. Immunol. 150, 499-507
39. Roche, P.A. and Cresswell, P. (1990) Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding. Nature 345, 615-618
40. Bijlmakers, M.J. et al. (1994) Assembly of HLA DR1 molecules translated in vitro: binding of peptide in the endoplasmic reticulum precludes association with invariant chain. EMBOJ. 13, 2699-2707
41. Schaiff, W.T. et al. (1992) HLA-DR associates with specific stress proteins and is retained in the endoplasmic reticulum in invariant chain negative cells. J. Exp. Med. 176, 657-666
42. Busch, R. et al. (1996) Invariant chain protects class II histocompatibility antigens from binding intact polypeptides in the endoplasmic reticulum. EMBO J. 15, 418-428
43. Bodmer, H. et al. (1994) Diversity of endogenous epitopes bound to MHC class II molecules limited by invariant chain. Science 263, 1284-1286
44. Long, E.O. et al. (1994) Invariant chain prevents the HLA-DR-restricted presentation ofa cytosolic peptide. J. Immunol. 153, 1487-1494
45. Dodi, A.I. et al. (1994) The invariant chain inhibits presentation of endogenous antigens by a human fibroblast cell line. Eur. J. Immunol. 24, 1632-1639
46. Lightstone, L. et al. (1997) In the absence of the invariant chain, HLA-DR molecules display a distinct array of peptides which is influenced by the presence or absence of HLA-DM. Proc. Natl. Acad. Sci. U. S. A. 94, 5772-5777
47. Viville, S. et al. (1993) Mice lacking the MHC class II-associated invariant chain. Cell 72, 635-648
48. Chervonsky, A.V. et al. A segment of the MHC class II beta chain plays a critical role in targeting class II molecules to the endocytic pathway. Int. Immunol. 6, 973-982
49. Busch, R. et al. (1995) Poor loading of major histocompatibility complex class II molecules with endogenously synthesized short peptides in the absence of invariant chain. Eur. J. Immunol. 25, 48-53
50. Siegrist, C.A. et al. (1995) A novel antigen-processing-defective phenotype in major histocompatibility complex class II-positive CIITA transfectants is corrected by interferon-gamma. J. Exp. Med. 182, 1793-1799
51. Huang, A.Y. et al. (1996) Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med. 183, 769-776
52. Ostrand-Rosenberg, S. et al. (1996) Expression of MHC class II and B-7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells. Tissue Antigens 47, 414-421